SpringerLink
Log in

Comparison of inhibitors of renin–angiotensin–aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

The adaptation of steroid therapy and the effect of renin–angiotensin–aldosterone system inhibitors (RASIs) for advanced immunoglobulin A nephropathy (IgAN) patients with impaired renal function are still controversial.

Methods

We divided 63 IgAN patients with an estimated glomerular filtration rate (eGFR) of <60 ml/min/1.73 m2 and proteinuria ≥ 0.5 g/day into two groups: the RASI group (RASI, n = 33), treated with RASIs alone; and the combination group (COMBI, n = 30), treated with corticosteroids and RASIs. We analyzed the clinical and histological background, renal survival rate, and the risk factors for progression.

Results

Renal function (mean eGFR: COMBI 46.4 vs. RASI 47.0 ml/min/1.73 m2), the amount of proteinuria (median: COMBI 1.39 vs. RASI 1.17 g/g creatinine) and histological backgrounds were not significantly different between the groups, but urinary red blood cells (U-RBCs) were significantly higher in the COMBI group than in the RASI group (median: COMBI 30.0 vs. RASI 10.0 counts/high-power field, P = 0.0171). The serial change in proteinuria did not differ until 5 years after treatment, but U-RBCs were significantly decreased in both groups (P < 0.0001), and eGFR was significantly decreased in the RASI group (P < 0.001) but not in the COMBI group. The results for each year after treatment did not differ significantly between both groups. The renal survival rate was not significantly different between the groups. There was no independent risk factor for progression by Cox regression analysis.

Conclusion

Combination therapy with steroids and RASIs was not superior to monotherapy with RASIs for advanced IgAN with impaired renal function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Locatelli F, Del Vecchio L, Pozzi C. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors. Nat Clin Pract. 2006;2:24–31.

    Article  CAS  Google Scholar 

  2. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005;16:1097–2088.

    Article  Google Scholar 

  3. Tumlin JA, Madaio MP, Hennigar R. Idiopthic IgA nephropathy: pathogenesis, histopathology, and therapeutic options. Clin J Am Soc Nephrol. 2004;2:1054–61.

    Article  Google Scholar 

  4. Cheng J, Zhang X, Zhang W, He Q, Tao X, Chen J. Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. Am J Nephrol. 2009;30:315–22.

    Article  PubMed  CAS  Google Scholar 

  5. Strippoli GFM. IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice. Am J Kidney Dis. 2009;53:5–8.

    Article  PubMed  Google Scholar 

  6. Dillon JJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Semin Nephrol. 2004;24:218–24.

    Article  PubMed  CAS  Google Scholar 

  7. Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomized controlled trials. Int J Clin Pract. 2009;63:880–8.

    Article  PubMed  CAS  Google Scholar 

  8. Chan JCM, Trachtman H. Modulating the progression in IgA nephropathy. Nephron Clin Pract. 2006;104:61–8.

    Article  Google Scholar 

  9. Dillon JJ. Treating IgA nephropathy. J Am Soc Nephrol. 2001;12:846–7.

    PubMed  CAS  Google Scholar 

  10. Ballardie FW. Quantitative appraisal of treatment options for IgA nephropathy. J Am Soc Nephrol. 2007;18:2806–9.

    Article  PubMed  CAS  Google Scholar 

  11. Laville M, Alamartine E. Treatment options for IgA nephropathy in adults: aproposal for evidence-based strategy. Nephrol Dial Transpl. 2004;19:1947–51.

    Article  Google Scholar 

  12. Moriyama T, Honda K, Nitta K, Yumura W, Nihei H. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function. Clin Exp Nephrol. 2004;8:237–42.

    Article  PubMed  CAS  Google Scholar 

  13. Moriyama T, Amamiya N, Ochi A, Tsuruta Y, Shimizu A, Kojima C, et al. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function. Clin Exp Nephrol. 2011;15:700–07.

    Google Scholar 

  14. Moriyama T, Amemiya N, Ochi A, Tsuruta Y, Shimizu A, Itabashi M, et al. Comparison of steroids and angiotensin receptor blockers for patients with advanced IgA nephropathy and impaired renal function. Am J Nephrol. 2011;34:233–40.

    Article  PubMed  CAS  Google Scholar 

  15. Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, third version. Nippon **zo Gakkai Shi 2001; 53:123–135.

  16. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transpl. 2009;24:3694–701.

    Article  CAS  Google Scholar 

  17. Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, et al. Combination therapy of prednisolone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009;53:26–32.

    Article  PubMed  CAS  Google Scholar 

  18. Choi S, Lee D, Jeong KH, Moon JY, Lee SH, Lee TW, et al. Prognostic relevance of clinical and histological features in IgA nephropathy treated with steroid and angiotensin receptor blockers. Clin Nephrol. 2009;72:353–9.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Kidney Center, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    Takahito Moriyama, Kayu Nakayama, Ayami Ochi, Nobuyuki Amemiya, Yuki Tsuruta, Chiari Kojima, Mitsuyo Itabashi, Takashi Takei, Keiko Uchida & Kosaku Nitta

Authors
  1. Takahito Moriyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kayu Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ayami Ochi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nobuyuki Amemiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuki Tsuruta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chiari Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mitsuyo Itabashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takashi Takei
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Keiko Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kosaku Nitta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takahito Moriyama.

About this article

Cite this article

Moriyama, T., Nakayama, K., Ochi, A. et al. Comparison of inhibitors of renin–angiotensin–aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function. Clin Exp Nephrol 16, 231–237 (2012). https://doi.org/10.1007/s10157-011-0545-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-011-0545-7

Keywords

Search

Navigation